Hbm Holdings Limited is a biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology, metabolism, and the central nervous system. The company operates through three core pillars: Harbour Therapeutics, which advances a global portfolio of transformative therapeutics; Harbour Medical, which leverages regional clinical development capabilities; and Nona Biosciences, which provides open access to the group's technologies and expertise. Its proprietary Harbour Mice® platform generates fully human monoclonal antibodies in both conventional and heavy chain-only formats, supporting the development of HBICE® bispecific antibodies and HCAb PLUS™ multi-specific medicines. The company also utilizes the Hu-mAtrIx™ AI platform to power a fully human Generative AI HCAb Model. Hbm Holdings serves global markets through internal research and development, strategic collaborations for co-discovery and co-development, and technology licensing. It maintains R&D centers in China, the United States, and Europe, and partners with academic institutions and pharmaceutical companies to address unmet medical needs.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage harbourbiomed.com
Sector Healthcare IR page harbourbiomed.com/investor
Tags
antibody therapeutics, immunology, oncology, metabolism, central nervous system, bispecific antibodies, generative ai, transgenic mice, clinical development, technology licensing, Harbour Therapeutics, Harbour Medical, Nona Biosciences, Harbour Mice, HBICE, HCAb PLUS, Hu-mAtrIx, Harbour BioMed-AstraZeneca Innovation Lab
Press page harbourbiomed.com/news

Metrics

Valuation  
Market cap HK$ 8.57B
Market cap (USD) $ 1.092B
P/E 10.95
PEG —
P/BV 2.38
P/S 6.10
P/OCF 205.03
P/FCF —
Dividend yield —
Turnover / mcap 0.44%
Returns  
ROE 37.2%
ROI 21.6%
ROIC 21.6%
Profit margin 57.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 16.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score 25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 157.975M 38.1M 89.502M 40.659M 4.308M 14.107M 5.419M
Net profit 91.333M 2.778M 22.797M -137.222M -137.777M -296.397M -67.46M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 1.86 0.45 0.38 0.38 0.87 1.34 —
Price performance 12m 3.14 0.17 0 -0.56 -0.35 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Hbm Holdings Limited (ticker 2142), listed in Hong Kong.

ETFs Holding Hbm Holdings Limited

ETF Weight in ETF Shares Market value As of
DFEM 0.01% 435,000 $ 606.643K Nov 12, 2026